KR20100087705A - 인간 탯줄로부터 전구 세포를 분리하고 보존하기 위한 최적화되고 규정된 방법 - Google Patents
인간 탯줄로부터 전구 세포를 분리하고 보존하기 위한 최적화되고 규정된 방법 Download PDFInfo
- Publication number
- KR20100087705A KR20100087705A KR1020107009850A KR20107009850A KR20100087705A KR 20100087705 A KR20100087705 A KR 20100087705A KR 1020107009850 A KR1020107009850 A KR 1020107009850A KR 20107009850 A KR20107009850 A KR 20107009850A KR 20100087705 A KR20100087705 A KR 20100087705A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- cell
- umbilical cord
- human umbilical
- selection method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000003954 umbilical cord Anatomy 0.000 title claims abstract description 75
- 238000000034 method Methods 0.000 title claims abstract description 56
- 239000002243 precursor Substances 0.000 title claims abstract description 11
- 238000002955 isolation Methods 0.000 title claims description 5
- 238000004321 preservation Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 354
- 210000000130 stem cell Anatomy 0.000 claims abstract description 25
- 230000035755 proliferation Effects 0.000 claims abstract description 19
- 230000012010 growth Effects 0.000 claims abstract description 12
- 238000002659 cell therapy Methods 0.000 claims abstract description 11
- 210000001519 tissue Anatomy 0.000 claims description 64
- 230000029087 digestion Effects 0.000 claims description 58
- 239000000243 solution Substances 0.000 claims description 48
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 43
- 239000012091 fetal bovine serum Substances 0.000 claims description 37
- 238000011534 incubation Methods 0.000 claims description 37
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 36
- 239000001963 growth medium Substances 0.000 claims description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 30
- 238000011084 recovery Methods 0.000 claims description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 26
- 238000005138 cryopreservation Methods 0.000 claims description 26
- 230000004069 differentiation Effects 0.000 claims description 25
- 102000004190 Enzymes Human genes 0.000 claims description 21
- 108090000790 Enzymes Proteins 0.000 claims description 21
- 229940088598 enzyme Drugs 0.000 claims description 21
- 229930182555 Penicillin Natural products 0.000 claims description 18
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 18
- 229940049954 penicillin Drugs 0.000 claims description 18
- 238000010187 selection method Methods 0.000 claims description 18
- 229960005322 streptomycin Drugs 0.000 claims description 18
- 239000006285 cell suspension Substances 0.000 claims description 17
- 239000006228 supernatant Substances 0.000 claims description 16
- 102000029816 Collagenase Human genes 0.000 claims description 15
- 108060005980 Collagenase Proteins 0.000 claims description 15
- 229960002424 collagenase Drugs 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 15
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 13
- 238000005119 centrifugation Methods 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 12
- 108090000631 Trypsin Proteins 0.000 claims description 12
- 102000004142 Trypsin Human genes 0.000 claims description 12
- 238000004113 cell culture Methods 0.000 claims description 12
- 230000001079 digestive effect Effects 0.000 claims description 12
- 239000012588 trypsin Substances 0.000 claims description 12
- 208000007536 Thrombosis Diseases 0.000 claims description 11
- 238000000926 separation method Methods 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 230000009471 action Effects 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 210000001691 amnion Anatomy 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 229940088710 antibiotic agent Drugs 0.000 claims description 8
- 238000010494 dissociation reaction Methods 0.000 claims description 8
- 230000005593 dissociations Effects 0.000 claims description 8
- 239000008188 pellet Substances 0.000 claims description 8
- 210000001789 adipocyte Anatomy 0.000 claims description 7
- 239000007640 basal medium Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 239000002054 inoculum Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 210000004498 neuroglial cell Anatomy 0.000 claims description 7
- 210000002569 neuron Anatomy 0.000 claims description 7
- 210000000963 osteoblast Anatomy 0.000 claims description 7
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 6
- 102100032912 CD44 antigen Human genes 0.000 claims description 6
- 102100037241 Endoglin Human genes 0.000 claims description 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 6
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 6
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 6
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 6
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 6
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 6
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 6
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 6
- 210000001612 chondrocyte Anatomy 0.000 claims description 6
- 239000005549 deoxyribonucleoside Substances 0.000 claims description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 239000002342 ribonucleoside Substances 0.000 claims description 6
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 5
- 238000013019 agitation Methods 0.000 claims description 5
- 238000005194 fractionation Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000003068 static effect Effects 0.000 claims description 5
- -1 CD31 Proteins 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 238000006911 enzymatic reaction Methods 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 238000009834 vaporization Methods 0.000 claims description 3
- 230000008016 vaporization Effects 0.000 claims description 3
- 230000023555 blood coagulation Effects 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000008174 sterile solution Substances 0.000 claims description 2
- 210000002435 tendon Anatomy 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 210000000981 epithelium Anatomy 0.000 claims 12
- 230000010261 cell growth Effects 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 4
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 3
- 230000000699 topical effect Effects 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 2
- 210000003850 cellular structure Anatomy 0.000 claims 2
- 239000000284 extract Substances 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108010067787 Proteoglycans Proteins 0.000 claims 1
- 102000016611 Proteoglycans Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000003140 astrocytic effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 210000003372 endocrine gland Anatomy 0.000 claims 1
- 210000003560 epithelium corneal Anatomy 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 210000000442 hair follicle cell Anatomy 0.000 claims 1
- 230000017525 heat dissipation Effects 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000009593 lumbar puncture Methods 0.000 claims 1
- 210000004705 lumbosacral region Anatomy 0.000 claims 1
- 210000004379 membrane Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 210000004248 oligodendroglia Anatomy 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 239000008196 pharmacological composition Substances 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 239000002344 surface layer Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 230000008014 freezing Effects 0.000 abstract description 8
- 238000007710 freezing Methods 0.000 abstract description 8
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 238000011194 good manufacturing practice Methods 0.000 abstract 2
- 210000005260 human cell Anatomy 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 41
- 238000005457 optimization Methods 0.000 description 15
- 238000010257 thawing Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000012981 Hank's balanced salt solution Substances 0.000 description 11
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 11
- 230000003833 cell viability Effects 0.000 description 9
- 230000006862 enzymatic digestion Effects 0.000 description 9
- 210000004700 fetal blood Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 7
- 230000002900 effect on cell Effects 0.000 description 7
- 229930182816 L-glutamine Natural products 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 230000009816 chondrogenic differentiation Effects 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 108010004729 Phycoerythrin Proteins 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 230000020477 pH reduction Effects 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 4
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 4
- 108010003272 Hyaluronate lyase Proteins 0.000 description 4
- 102000001974 Hyaluronidases Human genes 0.000 description 4
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 108010059712 Pronase Proteins 0.000 description 4
- 102000004987 Troponin T Human genes 0.000 description 4
- 108090001108 Troponin T Proteins 0.000 description 4
- 102000004243 Tubulin Human genes 0.000 description 4
- 108090000704 Tubulin Proteins 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 208000036815 beta tubulin Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000002518 glial effect Effects 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 229960002773 hyaluronidase Drugs 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 230000009818 osteogenic differentiation Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000001625 cardiomyogenic effect Effects 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920002567 Chondroitin Polymers 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 2
- HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- MZIYRTZAYQIAHW-UHFFFAOYSA-N 1-methyl-8-(2-methylpropyl)-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)N(C)C(=O)C2=C1N=C(CC(C)C)N2 MZIYRTZAYQIAHW-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000013354 cell banking Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000007792 gaseous phase Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0604—Whole embryos; Culture medium therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT103843A PT103843B (pt) | 2007-10-04 | 2007-10-04 | Método de isolamento de células precursoras a partir do cordão umbilical humano |
| PT103843 | 2007-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20100087705A true KR20100087705A (ko) | 2010-08-05 |
Family
ID=40456372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107009850A Ceased KR20100087705A (ko) | 2007-10-04 | 2008-10-03 | 인간 탯줄로부터 전구 세포를 분리하고 보존하기 위한 최적화되고 규정된 방법 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9546353B2 (enExample) |
| EP (1) | EP2203555B1 (enExample) |
| JP (1) | JP5785394B2 (enExample) |
| KR (1) | KR20100087705A (enExample) |
| CN (1) | CN101868536B (enExample) |
| AU (1) | AU2008306442B2 (enExample) |
| BR (1) | BRPI0817522A2 (enExample) |
| CA (1) | CA2701907A1 (enExample) |
| EA (1) | EA025532B1 (enExample) |
| ES (1) | ES2582369T3 (enExample) |
| IL (1) | IL204788A (enExample) |
| MX (1) | MX2010003511A (enExample) |
| PT (1) | PT103843B (enExample) |
| WO (1) | WO2009044379A2 (enExample) |
| ZA (1) | ZA201002260B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2634545T3 (es) | 2010-06-01 | 2017-09-28 | Auxocell Laboratories, Inc. | Células madre nativas de la gelatina de Wharton y su purificación |
| US9234177B2 (en) | 2010-10-18 | 2016-01-12 | Sunshine Life Science & Technology Corp. | Human multipotent embryonic stem cell-like progenitor cells |
| TWI535377B (zh) * | 2011-09-01 | 2016-06-01 | Storage, culture and application of umbilical cord tissue and its derived cells | |
| ES2890126T3 (es) * | 2011-12-30 | 2022-01-17 | Amit Patel | Métodos y composiciones para la obtención clínica de una célula alogénica y usos terapéuticos |
| CN102550543B (zh) * | 2012-02-10 | 2014-04-16 | 四川新生命干细胞科技股份有限公司 | 用于保存脐带组织的液体 |
| CN103461322B (zh) * | 2012-06-07 | 2016-08-03 | 西比曼生物科技（上海）有限公司 | 用于冻存复苏后的细胞的保存液 |
| EP2756754B1 (de) | 2013-01-17 | 2017-01-04 | Vita 34 Ag | Verfahren zur Behandlung von Nabelschnurgewebe, insbesondere im Zusammenhang mit der Konservierung des Gewebes |
| WO2015181831A2 (en) * | 2014-05-24 | 2015-12-03 | Venkataramanaa Neelamkrishnan | A method for targettingglioblastoma with wharton jelly-mesenchymal stem cells (wj-msc) derived from human umbilical cord |
| JP2017533917A (ja) * | 2014-11-05 | 2017-11-16 | ティッシュテック，インク． | 神経成長および再生を促進するための組成物および方法 |
| WO2017004460A1 (en) * | 2015-06-30 | 2017-01-05 | Surgenex, LLC | Compositions and methods for flowable allograft tissue |
| WO2017096611A1 (zh) * | 2015-12-11 | 2017-06-15 | 郭镭 | 一种从脐带华通氏胶组织中分离培养脐带间充质干细胞的方法 |
| WO2019175773A1 (en) | 2018-03-12 | 2019-09-19 | Universidade Do Porto | Compositions for use in the treatment of musculoskeletal conditions and methods for producing the same leveraging the synergistic activity of two different types of mesenchymal stromal/stem cells |
| CN112342191A (zh) * | 2019-08-07 | 2021-02-09 | 路春光 | hMSC生产试剂盒开发和质量管理标准优化和体系建立 |
| CN111893092A (zh) * | 2020-06-28 | 2020-11-06 | 国大生命科学产业集团(深圳)有限公司 | 一种人脐带来源的间充质干细胞及其制备方法 |
| CN113025567A (zh) * | 2021-03-31 | 2021-06-25 | 中国人民解放军陆军特色医学中心 | 一种椎间盘单细胞的分离方法 |
| DE102021116694B4 (de) * | 2021-06-29 | 2023-03-09 | Promocell Gmbh | Wässrige Lösung zur Zellkonservierung |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT402890B (de) * | 1994-03-16 | 1997-09-25 | Berbi Gmbh | Verwendung von notoginsenosid r1 zur herstellung von arzneimitteln |
| JPWO2003080822A1 (ja) * | 2002-03-27 | 2005-07-28 | ニプロ株式会社 | 胎盤由来の間葉系細胞およびその医学的用途 |
| CA2633980A1 (en) * | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Improved composition for collecting and preserving placental stem cells and methods of using the composition |
| ES2524443T3 (es) * | 2006-11-13 | 2014-12-09 | DePuy Synthes Products, LLC | Expansión in vitro de células postparto usando microportadores |
-
2007
- 2007-10-04 PT PT103843A patent/PT103843B/pt active IP Right Grant
-
2008
- 2008-10-03 CA CA2701907A patent/CA2701907A1/en not_active Abandoned
- 2008-10-03 KR KR1020107009850A patent/KR20100087705A/ko not_active Ceased
- 2008-10-03 MX MX2010003511A patent/MX2010003511A/es active IP Right Grant
- 2008-10-03 JP JP2010527592A patent/JP5785394B2/ja not_active Expired - Fee Related
- 2008-10-03 WO PCT/IB2008/054067 patent/WO2009044379A2/en not_active Ceased
- 2008-10-03 US US12/680,604 patent/US9546353B2/en not_active Expired - Fee Related
- 2008-10-03 EP EP08807881.1A patent/EP2203555B1/en not_active Not-in-force
- 2008-10-03 ES ES08807881.1T patent/ES2582369T3/es active Active
- 2008-10-03 EA EA201000425A patent/EA025532B1/ru not_active IP Right Cessation
- 2008-10-03 BR BRPI0817522-5A2A patent/BRPI0817522A2/pt not_active Application Discontinuation
- 2008-10-03 AU AU2008306442A patent/AU2008306442B2/en not_active Ceased
- 2008-10-03 CN CN200880114557.0A patent/CN101868536B/zh not_active Expired - Fee Related
-
2010
- 2010-03-28 IL IL204788A patent/IL204788A/en not_active IP Right Cessation
- 2010-03-30 ZA ZA2010/02260A patent/ZA201002260B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010003511A (es) | 2010-09-10 |
| JP2010539970A (ja) | 2010-12-24 |
| JP5785394B2 (ja) | 2015-09-30 |
| AU2008306442B2 (en) | 2014-12-04 |
| EP2203555A2 (en) | 2010-07-07 |
| ZA201002260B (en) | 2011-06-29 |
| ES2582369T3 (es) | 2016-09-12 |
| EA201000425A1 (ru) | 2010-10-29 |
| IL204788A (en) | 2013-07-31 |
| EP2203555B1 (en) | 2016-04-13 |
| US20100216237A1 (en) | 2010-08-26 |
| CN101868536B (zh) | 2015-03-25 |
| PT103843A (pt) | 2008-01-09 |
| PT103843B (pt) | 2008-08-12 |
| CA2701907A1 (en) | 2009-04-09 |
| US9546353B2 (en) | 2017-01-17 |
| WO2009044379A2 (en) | 2009-04-09 |
| EA025532B1 (ru) | 2017-01-30 |
| WO2009044379A3 (en) | 2009-05-22 |
| CN101868536A (zh) | 2010-10-20 |
| IL204788A0 (en) | 2010-12-30 |
| AU2008306442A1 (en) | 2009-04-09 |
| BRPI0817522A2 (pt) | 2014-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20100087705A (ko) | 인간 탯줄로부터 전구 세포를 분리하고 보존하기 위한 최적화되고 규정된 방법 | |
| EP2414511B1 (en) | Isolation of human umbilical cord blood-derived mesenchymal stem cells | |
| JP2010539970A5 (enExample) | ||
| Gao et al. | Expression pattern of embryonic stem cell markers in DFAT cells and ADSCs | |
| WO2011101834A1 (en) | A method for obtaining mesenchymal stem cells, media, methods and composition thereof | |
| KR20100084620A (ko) | 조직 재생을 위한 세포 조성물 | |
| US8796020B2 (en) | Manufacturing process for fresh and frozen stem cells | |
| Mattei et al. | Validated methods for isolation and qualification of mesenchymal stromal/stem cells from different sources | |
| CN106417253A (zh) | 一种骨骼肌干细胞的冻存液和冻存方法 | |
| JP6721504B2 (ja) | 多能性幹細胞及び前駆細胞を生産するためのプロセス | |
| Ghoneim et al. | Isolation of bone Marrow and adipose-derived mesenchymal stromal cells | |
| PT103844B (pt) | Método de isolamento de células precursoras a partir do cordão umbilical humano utilizando enzimas de origem vegetal | |
| TWI742399B (zh) | 無酵素前處理與培養脂肪間質幹細胞的方法 | |
| Sankaramaddi | Evaluation of human umbilical cord Wharton’s Jelly Cells as a potential cell source for cardiovascular tissue engineering |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20100504 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20131001 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20141118 Patent event code: PE09021S01D |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20150731 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20160531 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20150731 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20141118 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20160830 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20160531 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20171220 Appeal identifier: 2016101005099 Request date: 20160830 |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20160830 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20160830 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20160126 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20150317 Patent event code: PB09011R02I |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20161021 Patent event code: PE09021S01D |
|
| B601 | Maintenance of original decision after re-examination before a trial | ||
| PB0601 | Maintenance of original decision after re-examination before a trial | ||
| PJ0801 | Rejection of trial |
Patent event date: 20171220 Patent event code: PJ08011S01D Comment text: Decision on Dismissal of Request for Trial (Dismissal of Decision) Decision date: 20171220 Appeal kind category: Appeal against decision to decline refusal Appeal identifier: 2016101005099 Request date: 20160830 |